Combination of azelastine/fluticasone in the guidelines, recommendations and everyday clinical practice in the management of allergic rhinitis Review article
Article Sidebar
Main Article Content
Abstract
Allergic rhinitis (AR) is the most common allergic disease encountered in our daily clinical practice. Symptoms of AR occur in approximately 22.5% of Poles, and this disease significantly impairs the quality of life of patients, their ability to learn and work, constituting a significant problem for the healthcare system. AR often coexists with allergic conjunctivitis and represents a known risk factor for the development of bronchial asthma. Clinical studies have clearly shown that the combination of azelastine with fluticasone administered intranasally is characterized by a rapid onset of action and a long-lasting clinical effect. The reduction of symptoms using combination of azelastine with fluticasone is stronger than in the case of either of these drugs in monotherapy. Importantly, the clinical effect concerns not only AR but also the symptoms of co-occurring allergic conjunctivitis. ARIA standards emphasize the primary role of the combination of nasal corticosteroids with nasal antihistamines in the management of AR, especially in the case of more severe symptoms, chronic forms of AR and ineffectiveness of previously used therapies
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Samoliński B, Krzych-Fałta E, Piekarska B et al. ARIA-2019 – zintegrowana opieka w alergicznym nieżycie nosa – Polska. Alergologia Polska – Polish Journal of Allergology. 2019; 6(4): 111-26.
3. Bousquet J, Schunemann HJ, Togias A et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading Recommendations Assessment, Development and Evaluation (GRADE) and rea-world evidence. J Allergy Clin Immunol. 2020; 145: 70-80.
4. Samoliński B. Epidemiologia alergii i astmy w Polsce – doniesienie wstępne badania ECAP. Terapia. 2008; 208(4): 127-31.
5. Shaaban R, Zureik M, Soussan D et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008; 372(9643): 1049.
6. Kupczyk M. 5 powodów, dla których warto wdrożyć leczenie alergicznego nieżytu nosa przed okresem pylenia. Alergoprofil. 2024; 20(2): 3-7.
7. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998; 317(7173): 1624-9.
8. Prenner BM. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. J Asthma Allergy. 2016; 11(9): 135-43.
9. Zhong Z, Xun Y, Shi X et al. Clinical efficacy and safety of MP‑AzeFlu for the treatment of allergic rhinitis: a meta‑analysis. European Archives of Oto-Rhino-Laryngology. 2022; 279: 2457-64.
10. Tantilipkorn P, Kirtsreesakul V, Bunnag Ch et al. The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review. J Asthma Allergy. 2024; 17: 667-79.
11. Sousa-Pinto B, Vieira RJ, Bognanni A et al. Efficacy and safety of intranasal medications for allergic rhinitis: network meta-analysis. Allergy. 2025; 80(1): 94-105.
12. Torres MI, Gil-Mata S, Bognanni A et al. Intranasal versus oral treatments fot allergic rhinitis: a systematic review with meta-analysis. J Allergy Clin Immunol Pract. 2024; 12: 3404-18.